Her-2阳性进展期胃癌靶向治疗现状  

Present Status of Her-2 in Molecularly Targeted Therapy for Advanced Gastric Cancer

作　　者：戴飞飞[1] 池苗苗 王亚坤[1] 谢长生[2] 

机构地区：[1]浙江中医药大学第一临床医学院,浙江杭州310053 [2]浙江省中医院,浙江杭州310006

出　　处：《中国肿瘤》2015年第5期408-412,共5页China Cancer

基　　金：浙江省自然科学基金(LY13H290013);浙江省中医药科技计划项目(2013ZA043)

摘　　要：研究发现进展期胃癌存在不同程度的表皮生长因子受体2(Her-2)基因扩增和/或蛋白过表达。Her-2在胃癌中的阳性表达主要与胃癌的组织学类型和原发部位等具有密切相关性,而Her-2状态与患者预后的关系目前仍存在争议。针对Her-2阳性胃癌的分子靶向治疗药物研究已取得一些成果。全文对于胃癌中Her-2表达、Her-2与胃癌预后相关性及抗-Her-2靶向药物在Her-2阳性进展期胃癌中的治疗现状作一综述。Recently studies showed that advanced gastric cancer existing Her-2 protein overexpres- sion/gene amplification. Her-2 protein overexpression/gene amplification in gastric cancer is closely related to histological type and primary site. The relationship between Her-2 status and prognosis in gastric caner patients remains controversial. The molecular target treatment of Her-2 positive gastric cancer has made a lot of progress. The aim of this review is to summarize status of Her-2 protein expression in gastric cancer,the relationship between Her-2 gene and prognosis, and anti- Her-2 targeted drugs in gastric cancer.

关 键 词：胃癌 HER-2 分子靶向治疗 

分 类 号：R735.2[医药卫生—肿瘤]